Campbell & Co Investment Adviser’s Verona Pharma VRNA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,120	Closed	-$957K	–	1406
2025 Q2	$957K	Buy	10,120 +3,380	+50%	+$250K	0.06%	521
2025 Q1	$428K	Sell	6,740 -497	-7%	-$29.7K	0.03%	742
2024 Q4	$336K	Sell	7,237 -8,150	-53%	-$306K	0.03%	811
2024 Q3	$443K	Buy	+15,387	New	+$379K	0.03%	761
2024 Q1	–	Sell	-50,836	Closed	-$1.01M	–	1393
2023 Q4	$1.01M	Buy	50,836 +862	+2%	+$12.7K	0.09%	389
2023 Q3	$815K	Buy	+49,974	New	+$962K	0.1%	343

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Campbell & Co Investment Adviser's VRNA Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 10,120 shares — an estimated $957K sold.

Campbell & Co Investment Adviser first reported a position in VRNA in Q3 2023 and held it in 6 quarters. The position peaked at $1.01M in Q4 2023. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Campbell & Co Investment Adviser reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 10,120 Verona Pharma shares in Q3 2025, an estimated $957K.
Campbell & Co Investment Adviser first reported a position in Verona Pharma in Q3 2023 and held it in 6 quarters.
Campbell & Co Investment Adviser's Verona Pharma position peaked at $1.01M in Q4 2023.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.